indinavir + nelfinavir + stavudine + lamivudine

This regimen is an unbranded **four-drug antiretroviral combination** consisting of indinavir, nelfinavir, stavudine, and lamivudine, used in the treatment of *HIV-1 infection*. - **Indinavir** and **nelfinavir** are both *HIV-1 protease inhibitors* that block the viral protease enzyme, preventing the maturation of infectious virus particles. - **Stavudine** and **lamivudine** are *nucleoside reverse transcriptase inhibitors (NRTIs)*, which inhibit the reverse transcriptase enzyme, blocking the transcription of viral RNA into DNA, and halting HIV replication. - Combinations of these agents with two NRTIs plus one or more protease inhibitors are used to reduce viral load and delay resistance development. - Clinical studies have investigated combinations of stavudine and lamivudine with either indinavir or nelfinavir, showing efficacy and important impacts on adherence and tolerability, but there is *no known fixed-dose or branded co-formulation* of all four drugs together[5][2]. - This regimen is generally considered part of **Highly Active Antiretroviral Therapy (HAART)** for HIV; its primary indication is the treatment of HIV-1 infection in adults[2][5]. - There are no unique developers or exclusive manufacturers for this exact combination; rather, each agent is produced individually.